Q-omics provides the consensus-scored UBE2U profile across patient tissues and cancer cell-line models. UBE2U expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, UBE2U is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, UBE2U RNA expression shows 7,788 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, THCA, and TGCT as cancer lineages where UBE2U shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBE2U — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBE2U survival associations across molecular data types. UBE2U RNA expression shows survival associations in the most cancer types (14), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBE2U RNA expression–survival associations across cancer types. High UBE2U expression shows unfavorable associations in SCLC, READ, ACC, COAD and PAAD, but favorable associations in MESO. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for UBE2U RNA expression.
This table summarizes UBE2U tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for UBE2U. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBE2U shows lower tumor expression in THCA, KIRC, BRCA and ESCA and higher tumor expression in UCEC and LIHC. The THCA box plot shows higher UBE2U RNA expression in normal versus tumor tissue (log2 FC = −0.032, t-test p < 0.001).
This table shows molecular features associated with UBE2U in patient tissues and cancer cell lines. In patient samples, UBE2U shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, UBE2U RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and LIVER.
